Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Absorbable hemostats, the saga continues: FDA is again reopening the comment period on its proposed reclassification of absorbable hemostatic devices from high-risk class III to medium-risk class II status, the agency said Sept. 11. FDA first proposed the downclassification in October 2006 after hearing recommendations from an advisory panel in 2003, but criticism from current absorbable hemostat makers Ethicon and Ferrosan has delayed the process (1"The Gray Sheet" June 16, 2008, p. 3). The companies urged FDA to delay the final rule until an updated administrative record was made public. FDA complied, and has posted more than 30 additional items on the dockets since July 7. Comments on the proposed rule and accompanying draft special controls guidance are due Oct. 14
You may also be interested in...
Novartis Eyes Companion Test To Restart Approval Path For Struggling Med
Novartis has identified a genetic sequence that may be a risk factor for serious liver injury in patients receiving Prexige (lumiracoxib), a finding that may signal a path forward for the so-far troublesome development-stage COX-2 inhibitor
Novartis Eyes Companion Test To Restart Approval Path For Struggling Med
Novartis has identified a genetic sequence that may be a risk factor for serious liver injury in patients receiving Prexige (lumiracoxib), a finding that may signal a path forward for the so-far troublesome development-stage COX-2 inhibitor
CDRH Chief Pushes Office To Speed Up Device Reclassifications
FDA's device chief is putting more pressure on his office to get final device reclassifications out the door, and plans to release several more of them soon